山东新华制药股份(00719.HK)：获得硫酸氨基葡萄糖胶囊药品注册证书

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - The company has announced the receipt of a drug registration certificate for Glucosamine Sulfate Capsules [1] - The clinical application of the product focuses on treating osteoarthritis, indicating a strategic move into the growing market for joint health [1]